More study data available!
Data has been uploaded for 1 clinical trial and 4 antibody screening studies including:
- CAVD 446 (Nussenzweig) — dose escalation study of 3BNC117 monoclonal antibody (mAb) in HIV-infected and HIV-uninfected volunteers.
- CAVD 505 (Pantaleo) — study to further characterize the LN01 mAbs.
- CAVD 536 (Haynes) — study to characterize new DH512 clone antibodies.
- CAVD 553 (Montefiori) — study to assess potency and breadth of N6 mAb.
- CAVD 554 (Barouch) — study to characterize new PGDM1400 clone antibodies.
Click on the study page links below for Protocol Team reports, data summaries, and more details about the studies.
Data was uploaded for the following studies:
|
Name & Description |
Data Added |
Type |
PI |
Strategy |
|
CAVD 446 (Protocol # MCA-835) is a Phase 1, open label, dose-escalation study of the safety, pharmacokinetics and antiretroviral activity of 3BNC117 monoclonal antibody in HIV-infected and HIV-uninfected volunteers |
PK MAB |
Phase I |
Michel Nussenzweig |
Prophylactic neutralizing Ab |
|
CAVD 505 is an immunogenicity study to further characterize broadly neutralizing antibodies isolated from the germinal center B cells from the lymph node |
NAB MAB |
Antibody Screening |
Giuseppe Pantaleo |
Prophylactic neutralizing Ab |
|
CAVD 536 is an immunogenicity study comparing DH512 clone antibodies to original DH512 |
NAB MAB |
Antibody Screening |
Bart Haynes |
Prophylactic neutralizing Ab |
|
CAVD 553 is an immunogenicity study to characterize the potency and breadth of the bNAb, N6 |
NAB MAB |
Antibody Screening |
David Montefiori |
Prophylactic neutralizing Ab |
|
CAVD 554 is an immunogenicity study to characterize new PGDM1400 clone antibodies |
NAB MAB |
Antibody Screening |
Dan Barouch |
Prophylactic neutralizing Ab |